KIT/PDGFRA/KDR amplification defines a novel molecular subtype of adenoid cystic carcinoma patients who may benefit from treatment with tyrosine kinase inhibitors
Authors:
Open Access
- 1 August 2020
- journal article
- research article
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 9 (8) , 4703-4714
Abstract
Background: Adenoid cystic carcinoma (ACC) is a rare cancer with an aggressive phenotype and the high incidence of recurrence and distant metastasis severely affects the overall survival of ACC patients. Understanding the molecular mechanisms that drives ACC could improve the treatment and outcomes of patients with this disease. Methods: Actionable genetic alterations in 52 surgically resected ACC tissue samples were identified using targeted next generation sequencing (NGS). Expression of c-KIT/PDGFRα/VEGFR2 was assessed by immunohistochemistry (IHC). Sunitinib, a multi-targeted small molecule inhibitor of receptor tyrosine kinases (RTKs), was used off-label in one ACC patient harboring the KIT/PDGFRA/KDR amplification. Results: Potentially actionable genetic alterations were detected in 61.5% (32/52) of patients. In addition to the common actionable targets identified in NOTCH signaling and FGF/PI3K pathway, multiple novel gene fusions were detected in 7.7% (4/52) of ACC patients. Specifically, the KIT/PDGFRA/KDR amplification was identified in 2 of 52 (3.8%) cases and triple positive c-KIT/PDGFRα/VEGFR2 by IHC was associated with a significantly higher likelihood of distant metastasis. Furthermore, an advanced ACC patient with the KIT/PDGFRA/KDR amplification and who was positive for three encoded proteins showed a partial response to sunitinib. Conclusions: A total of 61.5% of ACC patients were found to harbor at least one actionable genetic alteration via a targeted NGS in this study. The KIT/PDGFRA/KDR amplification as well as triple positive c-KIT/PDGFRα/VEGFR2 defined a distinctive molecular phenotype that was characterized by distant metastasis. Clinical trials investigating the application of RTKs in ACC patients with the KIT/PDGFRA/KDR amplification or triple positive c-KIT/PDGFRα/VEGFR2 are warranted.Keywords
This publication has 38 references indexed in Scilit:
- Distinct Phenotypic Differences Associated with Differential Amplification of Receptor Tyrosine Kinase Genes at 4q12 in GlioblastomaPLOS ONE, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- CONTRA: copy number analysis for targeted resequencingBioinformatics, 2012
- Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinomaCancer Biology & Therapy, 2011
- Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic reviewThe Lancet Oncology, 2011
- Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: A reviewHead & Neck, 2011
- Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based studyNeuropathology, 2011
- PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomasGenes & Development, 2010
- The 4q12 Amplicon in Malignant Peripheral Nerve Sheath Tumors: Consequences on Gene Expression and Implications for Sunitinib TreatmentPLOS ONE, 2010
- High-resolution array comparative genomic hybridization analysis of human bronchial and salivary adenoid cystic carcinomaLaboratory Investigation, 2008